OCT 05, 2017 01:19 PM PDT

Brand New DNA-Based Zika Vaccine Provides Complete Protection

WRITTEN BY: Kara Marker

The newest leap forward in Zika virus vaccine development is probably the most exciting yet. The vaccine, a DNA-based approach, was found to be both safe and effective at revving up the immune system to protect infected mice from Zika.

University of Pennsylvania scientists, in collaboration with The Wistar Institute, Inovio Pharmaceuticals, and GeneOne Life Science, Inc., created GLS-5700, a synthetic DNA vaccine, which was tested for safety in a Phase 1 clinical trial in humans and for efficacy in mice models of Zika virus infection.

While researchers did not infect human participants with Zika virus to make sure the vaccine was working, they were able to confirm that the vaccine successfully evoked an immune response against the Zika virus in just three doses over several weeks. The safety trial included 40 participants; half received a one milligram dose of the vaccine, the other half received two milligrams.

All of the participants developed Zika-specific antibodies, and a large majority (80 percent) developed significant neutralizing antibodies, which neutralize the effects of the virus as opposed to binding and tagging them for destruction by other immune cells. Participants reported little to no adverse effects, only injection site pain, redness, and swelling, which you might see with any vaccine injection.

"This novel DNA vaccine was developed and implemented in just months via a platform that has advantages in temperature stability, storage, dose, and distribution compared to most traditional vaccines, making DNA vaccines an important tool to respond quickly to curb an emerging epidemic,” explained co-lead author The Wistar Institute’s David Weiner, PhD.

The blood from the human patients injected with the vaccine (containing the Zika-specific and neutralizing antibodies) successfully protected immunocompromised mice that had been exposed to the Zika virus.

"With these new results, we are one step closer to hopefully finding a way to prevent infection, which can cause serious birth defects and developmental delays in babies born to women who are infected with Zika,” said lead author Pablo Tebas, MD.

More studies will be done to ensure the vaccine will be effective at stimulating the immune system and preventing disease in humans. Tebas believes the new vaccine has “great promise” for being applied also to Chikungunya, West Nile Virus, Pandemic Influenza and Ebola.

The present study was published in the New England Journal of Medicine.

Sources: Medscape, University of Pennsylvania School of Medicine

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUN 12, 2018
Cancer
JUN 12, 2018
CD44 Insights & Cancer Influence
CD44 is a known cell surface protein involved in numerous interactions; it is overexpressed in cancerous tissue and its isoforms are being investigated as targets for cancer immunotherapy...
JUN 30, 2018
Immunology
JUN 30, 2018
CD4 T Cells Responsible for Inflammatory Bowel Disease
A specific subset of immune cells could be targeted to better treat inflammatory bowel disease (IBD). A new University of Alabama at Birmingham study point...
JUL 30, 2018
Immunology
JUL 30, 2018
Traumatic Childhood to Addiction, an Immune System Problem
Childhood adversity alters the immune system which contributes to increased risk of addiction as an adult....
AUG 04, 2018
Immunology
AUG 04, 2018
Infant's Innate Immune Response
An infant's innate immune response develops from fetus to birth, but it may not be as "immature" as previously thought....
AUG 08, 2018
Immunology
AUG 08, 2018
Doxorubicin Causes Heart Toxicity by Immune System Disruption
Chemotherapy drug Doxorubicin disrupts metabolism that controls immune responses in the heart leading to heart toxicity....
SEP 05, 2018
Immunology
SEP 05, 2018
B Cells Contribute to Brain Lesions in Multiple Sclerosis
B cells lead to T cell activation resulting in damage to the myelin sheath and brain cells in multiple sclerosis pathogenesis....
Loading Comments...